Accelerated Corneal Collagen Crosslinking Protocols

Status Recruiting

Clinical Trial Summary

To evaluate and compare the effect of pulsed light (pl-ACXL) accelerated and continuous light accelerated (cl-ACXL) epithelium-off cross-linking in halting the progression of keratoconus.

Clinical Trial Description

Keratoconus (KC), which was first described in detail in 1854, is the most common corneal primary ectasia and is characterized by progressive bilateral and asymmetric corneal thinning and bulging outward into a cone-like shape that can severely impact patients' vision. Keratoconus usually develops in the second and third decades of life and progresses until the fourth decade. It was thought to be a rare corneal disease. Despite a great deal of research, no one theory explains it all and it may be caused by a combination of things. However, Meek proposed that the loss of structural integrity in the KC cornea was caused by the presence of abnormal keratocytes and matrix proteins and upregulated proteolysis triggered an unravelling of lamellae along their length and from their anchors at the limbus, with an opening of the lamellar bifurcations. This theory is supported by observations following riboflavin/UVA collagen cross-linking, where the proposed cross-linkage of the tissue increases both the resistance of the stroma to enzymatic digestion and the cohesiveness between collagen fibrils and the non-collagenous matrix. Conventional CXL (CXL) with a continuous irradiation of 3 mW/cm2 for 30 min is considered safe and effective in the prevention of keratoconus progression according to different clinical trials. nevertheless, the procedure is time-consuming, lasting around 1 h, which may lead to patient discomfort and reduced physician working efficiency. With evolving technical advances, commercially available UV light sources have been developed, making CXL more efficient with shorter UV exposure times, higher UV intensities, and pulsed light compared with continuous light settings. Various accelerated CXL protocols have been described and its effect on biomechanical properties on corneas stated as equal to the standard protocol. Ex-vivo studies also suggest a distinction between various accelerated CXL protocols by providing evidence for a drop in efficiency with increased UV illumination intensity while maintaining equal surface energy. In this study we evaluate the two types of "accelerated crosslinking". ;

Study Design

Related Conditions & MeSH terms

Keratoconus

Clinical Trial Details

NCT number	NCT05693740
Study type	Interventional
Source	Assiut University
Contact	rana mostafa, bachelor
Phone	01095759179
Email	ratycat222@yahoo.com
Status	Recruiting
Phase	N/A
Start date	August 1, 2022
Completion date	March 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04570020` - Scleral Lens Fitting Using Wide-Field OCT
Recruiting	`NCT02921009` - McNeel Eye Center Corneal Crosslinking Study	N/A
Terminated	`NCT02762253` - Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.	Phase 2
Completed	`NCT01691651` - Botulinum Toxin A for the Treatment of Keratoconus	N/A
Completed	`NCT01527708` - Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas	N/A
Completed	`NCT01527721` - Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus	N/A
Recruiting	`NCT00841386` - Treatment of Keratoconus Using Collagen Cross-Linking	Phase 2/Phase 3
Completed	`NCT00347074` - A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients	N/A
Completed	`NCT03187912` - Accelerated Corneal Cross-linking With Different Riboflavin Solutions	Phase 3
Completed	`NCT00584285` - Corneal Topographer Fluorescein Patterns
Completed	`NCT03511495` - Reliability of Topography Measurements in Keratoconus
Not yet recruiting	`NCT05395650` - Cyanocobalamin as Photosensitizing Agent
Completed	`NCT04418999` - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus	Early Phase 1
Completed	`NCT05019768` - Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS	N/A
Completed	`NCT03235856` - Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE
Withdrawn	`NCT01789333` - Higher Irradiance in Keratoconus Ectasia	N/A
Completed	`NCT05114928` - Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
Completed	`NCT03647046` - Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus	N/A
Recruiting	`NCT04439552` - fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Recruiting	`NCT06100939` - Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.